Editing Flecainide (section)

==Medical uses==
Flecainide is used in the treatment of many types of [[supraventricular tachycardia]]s, including [[AV nodal reentrant tachycardia|AV nodal re-entrant tachycardia]] (AVNRT) and [[Wolff-Parkinson-White syndrome]] (WPW).

It also has limited use in the treatment of certain forms of [[ventricular tachycardia]] (VT). In particular, flecainide has been useful in the treatment of ventricular tachycardias that are not in the setting of an acute ischemic event. It has use in the treatment of right ventricular outflow tract (RVOT) tachycardia<ref name = Gill>{{cite journal | vauthors = Gill JS, Mehta D, Ward DE, Camm AJ | title = Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality | journal = British Heart Journal | volume = 68 | issue = 4 | pages = 392–397 | date = October 1992 | pmid = 1449923 | pmc = 1025139 | doi = 10.1136/hrt.68.10.392 }}</ref> and in the suppression of arrhythmias in [[arrhythmogenic right ventricular dysplasia]] (ARVD).<ref name = Sakurada>{{cite journal | vauthors = Sakurada H, Hiyoshi Y, Tejima T, Yanase O, Tokuyasu Y, Watanabe K, Motomiya T, Sugiura M, Hiraoka M | display-authors = 6 | title = [Effects of oral flecainide treatment of refractory tachyarrhythmias] | journal = Kokyu to Junkan. Respiration & Circulation | volume = 38 | issue = 5 | pages = 471–476 | date = May 1990 | pmid = 2115193 }}</ref> Studies (notably the [[Cardiac Arrhythmia Suppression Trial]]) have shown an increased mortality when flecainide is used to suppress ventricular [[Premature ventricular contraction|extrasystoles]] in the setting of acute myocardial infarction.<ref name = Echt>{{cite journal | vauthors = Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL | display-authors = 6 | title = Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial | journal = The New England Journal of Medicine | volume = 324 | issue = 12 | pages = 781–788 | date = March 1991 | pmid = 1900101 | doi = 10.1056/NEJM199103213241201 | doi-access = free }}</ref><ref name = Greenberg>{{cite journal | vauthors = Greenberg HM, Dwyer EM, Hochman JS, Steinberg JS, Echt DS, Peters RW | title = Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I | journal = British Heart Journal | volume = 74 | issue = 6 | pages = 631–635 | date = December 1995 | pmid = 8541168 | pmc = 484119 | doi = 10.1136/hrt.74.6.631 }}</ref>

In individuals suspected of having the [[Brugada syndrome]], the administration of flecainide may help reveal the [[electrocardiography|ECG]] findings that are characteristic of the disease process. This may help make the diagnosis of the disease in equivocal cases.<ref name = Gasparini>{{cite journal | vauthors = Gasparini M, Priori SG, Mantica M, Napolitano C, Galimberti P, Ceriotti C, Simonini S | title = Flecainide test in Brugada syndrome: a reproducible but risky tool | journal = Pacing and Clinical Electrophysiology | volume = 26 | issue = 1P2 | pages = 338–341 | date = January 2003 | pmid = 12687841 | doi = 10.1046/j.1460-9592.2003.00045.x | s2cid = 555793 }}</ref>

Flecainide has been introduced into the treatment of arrhythmias in children.

In the long-term, flecainide seems to be safe in people with a healthy heart with no signs of [[left ventricular hypertrophy]], [[ischemic heart disease]], or [[heart failure]].<ref>{{cite journal | vauthors = Aliot E, Capucci A, Crijns HJ, Goette A, Tamargo J | title = Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation | journal = Europace | volume = 13 | issue = 2 | pages = 161–173 | date = February 2011 | pmid = 21138930 | pmc = 3024037 | doi = 10.1093/europace/euq382 }}</ref>